Equity in STI Testing Act
- Sponsor
- Rep. Williams, Nikema [D-GA-5]
- Committees
- Natural Resources Committee (primary)
- Last action
- Jul 30, 2026
Bottom line
This bill expands access to essential sexually transmitted infection (STI) screening by eliminating out-of-pocket costs for beneficiaries across major federal health care programs.
What it actually does
This bill mandates that various federal health programs, including Medicare Advantage, Medicaid, CHIP, TRICARE, VA healthcare, and the Indian Health Service, cover screening tests for HIV, gonorrhea, syphilis, trichomoniasis, and chlamydia. Crucially, it prohibits the imposition of any cost-sharing requirements for these tests across all these programs, aiming to remove financial barriers to access.
Proponents argue
Proponents argue that eliminating cost-sharing for STI testing will significantly reduce barriers to care, leading to increased testing rates, earlier detection, and more timely treatment. They contend that this will ultimately curb the spread of STIs, improve public health outcomes, and address health disparities, particularly for vulnerable populations who rely on these federal programs.
Opponents contend
Potential opponents might raise concerns about the increased federal spending associated with expanding coverage and eliminating cost-sharing across multiple programs, especially given the absence of specified funding offsets. They could also argue that this bill represents an overreach of federal mandates into state-administered programs like Medicaid and CHIP, potentially straining state budgets and healthcare provider resources.
The bill is relatively short and clearly structured, making it accessible for an informed reader to understand its core provisions within a reasonable timeframe.
Section 2(a)
Mandated STI Testing Coverage in Medicare Advantage
This provision requires Medicare Advantage plans to cover screening tests for HIV, gonorrhea, syphilis, trichomoniasis, and chlamydia, including the administration of these tests, as an additional preventive service. This ensures that Medicare Advantage beneficiaries can access these critical tests without incurring any out-of-pocket expenses, thereby removing a significant financial barrier to preventive care.
Supporters argue
Supporters argue this closes a crucial gap in preventive care for seniors and individuals with disabilities covered by Medicare Advantage, promoting earlier detection and treatment of STIs, which can prevent more serious health complications.
Critics contend
Critics might argue that expanding mandated benefits increases the cost burden on Medicare Advantage plans, which could indirectly lead to higher premiums or reduced benefits in other areas, or that existing coverage is already adequate.
Tradeoffs
This provision balances the goal of expanding preventive health access and improving public health outcomes against potential increases in program costs for Medicare Advantage plans and, indirectly, for federal taxpayers.
Section 2(b)
Mandated STI Testing Coverage and Cost-Sharing Elimination in Medicaid
This provision mandates that state Medicaid programs cover screening tests for HIV, gonorrhea, syphilis, trichomoniasis, and chlamydia. It explicitly prohibits states from imposing any cost-sharing, such as copayments or deductibles, for these tests. This aligns Medicaid coverage with the preventive service requirements of the Public Health Service Act, ensuring low-income individuals have no financial barriers to these screenings.
Section 2(c)
Mandated STI Testing Coverage and Cost-Sharing Elimination in CHIP
This provision requires state Children's Health Insurance Programs (CHIP) to cover screening tests for HIV, gonorrhea, syphilis, trichomoniasis, and chlamydia for targeted low-income children. It also explicitly prohibits cost-sharing for these tests, ensuring that children and adolescents covered by CHIP can access these preventive services without financial barriers, promoting early detection and intervention.
Section 2(d)
Mandated STI Testing Coverage and Cost-Sharing Elimination in TRICARE
This provision expands TRICARE coverage to include screening tests for HIV, gonorrhea, syphilis, trichomoniasis, and chlamydia for members and former members of the uniformed services and their beneficiaries. It explicitly prohibits cost-sharing for these tests under TRICARE Prime, TRICARE Select, and TRICARE's extended care health option (ECHO), ensuring military families have no out-of-pocket costs for these screenings.
Section 2(e)
Mandated STI Testing Coverage and Cost-Sharing Elimination for Veterans
This provision requires the Department of Veterans Affairs (VA) to furnish screening tests for HIV, gonorrhea, syphilis, trichomoniasis, and chlamydia to eligible veterans enrolled in the VA healthcare system. It explicitly prohibits the VA from requiring any copayment or charging any other cost for these tests, ensuring that veterans can access these vital screenings without financial barriers.
Section 2(f)
Mandated STI Testing Coverage and Cost-Sharing Elimination for Indians Receiving Care through IHS
This provision requires the Secretary of Health and Human Services to cover, without cost-sharing, screening tests for HIV, gonorrhea, syphilis, trichomoniasis, and chlamydia for American Indians and Alaska Natives receiving health services through the Indian Health Service (IHS), including Urban Indian Organizations. This coverage applies regardless of whether the tests are authorized under the purchased/referred care system or as a direct IHS health service, ensuring equitable access.
The bill repeatedly references the condition "if such testing (or administration, as applicable) would be covered under health insurance coverage pursuant to section 2713(a)(1) of the Public Health Service Act for an individual enrolled under such coverage." This clause ensures that the mandated STI tests align with existing standards for preventive services under the Affordable Care Act (ACA), which generally requires non-grandfathered plans to cover certain preventive services without cost-sharing, based on recommendations from the U.S. Preventive Services Task Force (USPSTF).
Throughout Section 2(b), (c), (d), (e), and (f)
Why it matters:This is standard legislative practice to avoid redundancy and ensure consistency with existing federal health policy frameworks, particularly the ACA's preventive services mandate. It leverages an established definition rather than creating a new one, streamlining the legislative text.
Case for: Supporters argue that this cross-reference ensures consistency and alignment with established preventive care guidelines, preventing the creation of conflicting or redundant standards across federal health programs. It streamlines implementation by relying on existing, clinically-backed definitions.
Case against: Critics might argue that relying on an external, potentially evolving standard makes the bill's scope less transparent and could lead to future changes in covered services without direct congressional action on this specific bill, potentially reducing legislative oversight.
Estimated impact: Ensures that the specific STI tests mandated for coverage are those already recognized as preventive services under broader health insurance regulations, thus standardizing the scope of services across federal programs.